CCI approves acquisition of certain shareholding in Balaji Wafers by General Atlantic Singapore (See 'Corp Brief') CCI approves combination of Bagmane Prime Office REIT of Bagmane Developers and others (See 'Corp Brief') CCI okays acquisition of additional equity in Generali Central Insurance by Central Bank (See 'Corp Brief') India and Finland renew MoU on Environmental Cooperation (See 'Corp Brief') IPR - Proof of right refers to documents showing that applicant legally owns 'right to apply for patent', which can be established through assignment or employment agreement with inventor: HC (See 'Legal Desk') Crude and Petroleum procurement: 24×7 Control Room Monitoring Supply Position (See 'Corp Brief') On World Wildlife Day 2026, PM reaffirms Commitment to Wildlife Conservation (See 'Corp Brief') IBC - valuers must ensure a reasoned valuation report to guide stakeholders in economic decision-making during insolvency, including consideration of intangible assets where relevant: IBBI (See 'Legal Desk') GPS transforming fishing community lives in Car Nicobar (See 'Corp Brief') Competition Act - disputes concerning alteration of copyrighted content & associated rights, need not be entertained where no prima facie case of anti-competitive agreement or abuse of dominant position, is made out: CCI (See 'Legal Desk') Ministry of Steel holds Interactive Session with Global Diplomats Ahead of 'Bharat Steel 2026' (See 'Corp Brief') Khadse announces unique nationwide ASMITA League to mark International Women's Day (See 'Corp Brief') IPR – Anti-dissection rule, which requires trademarks to be compared as whole, does not apply where part of mark is proven to be dominant feature: HC (See 'Legal Desk') India Summit 2026: Major AI Investment Commitments made (See 'Corp Brief') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

CCI okays internal acquisition by Glaxo Smith Kline

Published: Jan 24, 2022

By TIOLCorplaws News Service

NEW DELHI, JAN 24, 2022: THE Competition Commission of India (CCI) approves acquisition by GlaxoSmithKline Consumer Healthcare Overseas Limited and GlaxoSmithKline Consumer Healthcare UK Trading Limited (Acquirers) of shareholding in GlaxoSmithKline Asia Private Limited (Target) under Section 31(1) of the Competition Act, 2002.

The Proposed Combination involves collective acquisition of 100% shares of the Target by the Acquirers. Further, prior to the proposed combination, GSKAPL will acquire the trademarks pertaining to "Iodex" and "Ostocalcium" brands in India alongwith the legal, economic, commercial and marketing rights of such brands and other associated assets (GSK Consumer Brands) from GlaxoSmithKline Pharmaceuticals Limited.

GlaxoSmithKline Consumer Healthcare Overseas Limited is a wholly-owned subsidiary of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited ("GSK CH HoldCo"). It is a part of the overall GlaxoSmithkline (GSK) group and its principal activity is to act as an investment holding company for GSK CH HoldCo and its subsidiaries.

GlaxoSmithKline Consumer Healthcare UK Trading Limited is a part of the overall GSK group and is a wholly-owned subsidiary of GSK CH HoldCo. It is engaged in the distribution and sale of consumer healthcare products, manufacturing, marketing, providing management services to the consumer healthcare group and providing research and development services to other consumer healthcare companies within the GSK group.

GSKAPL is a consumer healthcare company that is engaged in the marketing and distribution of oral healthcare products under various brand names such as Sensodyne, Parodontax, Polident and over-the-counter medicines products under the brand names such as Crocin, ENO. 

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.